MTNB stock icon

Matinas BioPharma
MTNB

0.6200 USD
-0.0144
2.27%
At close Nov 15, 4:00 PM EST
After hours
0.6154
-0.0046
0.74%
1 day
-2.27%
5 days
-12.68%
1 month
-82.18%
3 months
-91.90%
6 months
-92.82%
Year to date
-94.49%
1 year
-94.46%
5 years
-98.81%
10 years
-99.68%
 

About: Matinas BioPharma Holdings Inc is a clinical-stage biopharmaceutical company with a focus on identifying and developing novel pharmaceutical products. The firm's pipeline includes MAT2203, MAT2501, and others.

Employees: 34

Healthcare Pharmaceutical Preparations
0
Funds holding %
of 6,704 funds
–
Analysts bullish %

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

10.58% more ownership

Funds ownership: 15.52% [Q2] → 26.1% (+10.58%) [Q3]

65% less funds holding

Funds holding: 48 [Q2] → 17 (-31) [Q3]

68% less capital invested

Capital invested by funds: $6.16M [Q2] → $1.97M (-$4.19M) [Q3]

91% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 34

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 13

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for MTNB.

See Analyst Rankings

Financial journalist opinion

Neutral
GlobeNewsWire
2 weeks ago
Matinas BioPharma Announces the Termination of MAT2203 Partnership Negotiations and Implements Immediate Workforce Reduction
BEDMINSTER, N.J., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB) announces that negotiations under the previously disclosed non-binding term sheet regarding global rights to MAT2203, its oral formulation of amphotericin B, have been terminated following notification from the prospective partner. As a result, Matinas has implemented an 80% workforce reduction effective immediately, eliminating 15 positions including three members of senior management, and has ceased all product development activities to conserve cash.
Matinas BioPharma Announces the Termination of MAT2203 Partnership Negotiations and Implements Immediate Workforce Reduction
Neutral
Seeking Alpha
3 months ago
Matinas BioPharma Holdings, Inc. (MTNB) Q2 2024 Earnings Call Transcript
Matinas BioPharma Holdings, Inc. (NYSE:MTNB ) Q2 2024 Earnings Conference Call August 14, 2024 4:30 PM ET Company Participants Jody Cain – LHA Investor Relations Jerry Jabbour – Chief Executive Officer Keith Kucinski – Chief Financial Officer Terri Matkovits – Chief Development Officer Conference Call Participants Scott Henry – Alliance Global Partners Joanne Lee – Maxim Group Operator Welcome to the Matinas BioPharma Second Quarter 2024 Financial Results Conference Call. Currently all participants are in a listen-only mode.
Matinas BioPharma Holdings, Inc. (MTNB) Q2 2024 Earnings Call Transcript
Neutral
GlobeNewsWire
3 months ago
Matinas BioPharma Reports Second Quarter 2024 Financial Results and Provides a Business Update
Signs non-binding term sheet granting global rights to develop and commercialize oral MAT2203 for invasive aspergillosis and potentially other invasive fungal infections
Matinas BioPharma Reports Second Quarter 2024 Financial Results and Provides a Business Update
Neutral
GlobeNewsWire
3 months ago
Matinas BioPharma to Webcast Conference Call to Discuss Second Quarter 2024 Financial Results and Provide a Business Update on August 14, 2024
BEDMINSTER, N.J., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, announces that it will report second quarter 2024 financial results after market close on Wednesday, August 14, 2024. Matinas management will host an investment community conference call and webcast to discuss financial results and provide a business update that day at 4:30 p.m. Eastern time (1:30 p.m. Pacific time).
Matinas BioPharma to Webcast Conference Call to Discuss Second Quarter 2024 Financial Results and Provide a Business Update on August 14, 2024
Neutral
GlobeNewsWire
4 months ago
Matinas BioPharma Reports Successful Treatment of Patient with Limb-Threatening Mucor Infection in its Oral MAT2203 Compassionate/Expanded Use Access Program
BEDMINSTER, N.J., June 24, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, announces the recent successful treatment of a 22-year-old male with polymicrobial necrotizing fasciitis (flesh-eating disease) that involved drug-resistant Lichtheimia, an angio-invasive species of the fungus Mucorales. This patient was treated at New York Presbyterian/Weill Cornell Medical Center and was discharged after just six weeks of treatment with MAT2203, Matinas' oral formulation of the potent antifungal amphotericin B. The patient was treated under Matinas' Compassionate/ Expanded Use Access Program by Sharan Yadav, MD, Infectious Disease Fellow.
Matinas BioPharma Reports Successful Treatment of Patient with Limb-Threatening Mucor Infection in its Oral MAT2203 Compassionate/Expanded Use Access Program
Neutral
GlobeNewsWire
5 months ago
Matinas BioPharma's Oral MAT2203 to Be Featured in Fireside Chat Hosted by A.G.P. with Antifungal Expert Dr. David S.
BEDMINSTER, N.J., June 13, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, announces that MAT2203, its oral formulation of the potent antifungal amphotericin B, will be featured in a fireside chat with David S.
Matinas BioPharma's Oral MAT2203 to Be Featured in Fireside Chat Hosted by A.G.P. with Antifungal Expert Dr. David S.
Positive
InvestorPlace
6 months ago
Penny Stock Sleepers: 7 Under-the-Radar Gems Ready to Launch
Penny stocks to buy understandably offer many enticing attributes, not least of which is the potential for tremendous returns. Of course, the emphasis is on the word “potential.
Penny Stock Sleepers: 7 Under-the-Radar Gems Ready to Launch
Neutral
GlobeNewsWire
6 months ago
New In Vitro Data Showing Matinas BioPharma's LNC Platform Delivering Small Oligonucleotides Presented at TIDES USA 2024
BEDMINSTER, N.J., May 16, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, announces new in vitro data showing the use of LNCs for the delivery of small oligonucleotides was presented yesterday in a poster session at TIDES USA 2024: Oligonucleotide & Peptide Therapeutics, a hybrid in-person and virtual conference underway in Boston.
New In Vitro Data Showing Matinas BioPharma's LNC Platform Delivering Small Oligonucleotides Presented at TIDES USA 2024
Negative
InvestorPlace
6 months ago
MTNB Stock Earnings: Matinas BioPharma Hldgs Meets EPS for Q1 2024
Matinas BioPharma Hldgs (NYSEMKT: MTNB ) just reported results for the first quarter of 2024. Matinas BioPharma Hldgs reported earnings per share of -3 cents.
MTNB Stock Earnings: Matinas BioPharma Hldgs Meets EPS for Q1 2024
Neutral
Seeking Alpha
6 months ago
Matinas BioPharma Holdings, Inc. (MTNB) Q1 2024 Earnings Call Transcript
Matinas BioPharma Holdings, Inc. (NYSE:MTNB ) Q1 2024 Earnings Conference Call May 9, 2024 4:30 PM ET Company Participants Jody Cain - LHA Investor Relations Jerome Jabbour - Chief Executive Officer Theresa Matkovits - Chief Development Officer Terry Ferguson - Chief Medical Officer Keith Kucinski - Chief Financial Officer Conference Call Participants Scott Henry - Alliance Global Partners Operator Welcome, everyone, to the Matinas BioPharma First Quarter 2024 Financial Results Conference Call. Currently, all participants are in a listen-only mode.
Matinas BioPharma Holdings, Inc. (MTNB) Q1 2024 Earnings Call Transcript
See News Rankings
Charts implemented using Lightweight Charts™